Glutathione peroxidase 7 suppresses bile salt-induced expression of pro-inflammatory cytokines in Barrett's carcinogenesis

Journal of Cancer

Volumn 5, Issue 7, 2014, Pages 510-517

  Peng, Dun Fa ^a   Hu, Tian Ling ^a,c   Soutto, Mohammed ^a,c   Belkhiri, Abbes ^a   El Rifai, Wael ^a,b,c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Barrett's; Bile salts; Cancer; Cytokine; Esophagus; GERD; Glutathione; Inflammation; NF B; Reflux

Indexed keywords

BILE SALT; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYTOKINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 7; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; BARRETT ESOPHAGUS; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84902992764     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.9215     Document Type: Article

References (47)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49:33-64.
2. Picardo SL, Maher SG, O'Sullivan JN, Reynolds JV. Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig Surg. 2012; 29: 251-60. doi:10.1159/000341498.
3. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet. 2009; 373: 850-61. doi:10.1016/S0140-6736(09)60487-6.
4. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol. 1999; 94: 2037-42. doi:10.1111/j.1572-0241.1999.01275.x.
5. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med. 1986; 315: 362-71. doi:10.1056/NEJM198608073150605.
6. Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett's esophagus: a review of the literature. J Gastrointest Surg. 2011; 15: 708-18. doi:10.1007/s11605-011-1485-y.
7. Zhang HY, Spechler SJ, Souza RF. Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett. 2009; 275: 170-7. doi:10.1016/j.canlet.2008.07.006.
8. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004; 239: 491-500.
9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-7. doi:10.1038/nature01322.
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-45. doi:10.1016/S0140-6736(00)04046-0.
11. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441: 431-6. doi:10.1038/nature04870.
12. Katsha A, Soutto M, Sehdev V, Peng D, Washington MK, Piazuelo MB, et al. Aurora Kinase A Promotes Inflammation and Tumorigenesis in Mice and Human Gastric Neoplasia. Gastroenterology. 2013; doi:10.1053/j.gastro.2013.08.050.
13. Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, et al. Loss of TFF1 is associated with activation of NF-kappaB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest. 2011; 121: 1753-67. doi:10.1172/JCI43922.
14. Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog. 2006; 45:355-61. doi:10.1002/mc.20217.
15. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336: 1066-71. doi:10.1056/NEJM199704103361506.
16. Huo X, Juergens S, Zhang X, Rezaei D, Yu C, Strauch ED, et al. Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-kappaB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011; 301: G278-86. doi:10.1152/ajpgi.00092.2011.
17. Debruyne PR, Witek M, Gong L, Birbe R, Chervoneva I, Jin T, et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology. 2006; 130: 1191-206. doi:10.1053/j.gastro.2005.12.032.
18. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008; 18: 19-26. doi:10.1016/j.gde.2008.01.020.
19. Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. Biochim Biophys Acta. 2013; 1830: 3289-303. doi:10.1016/j.bbagen.2012.11.020.
20. Peng D, Belkhiri A, Hu T, Chaturvedi R, Asim M, Wilson KT, et al. Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells. Gut. 2012; 61: 1250-60. doi:10.1136/gutjnl-2011-301078.
21. Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, et al. Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells. J Biol Chem. 2004; 279: 43522-9. doi:10.1074/jbc. M407141200.
22. Wei PC, Hsieh YH, Su MI, Jiang X, Hsu PH, Lo WT, et al. Loss of the oxidative stress sensor NPGPx compromises GRP78 chaperone activity and induces systemic disease. Mol Cell. 2012; 48: 747-59. doi:10.1016/j.molcel.2012.10.007.
23. Peng D, Hu T, Soutto M, Belkhiri A, Zaika A, El-Rifai W. Glutathione peroxidase 7 has potential tumour suppressor functions that are silenced by location-specific methylation in oesophageal adenocarcinoma. Gut. 2013; doi:10.1136/gutjnl-2013-304612.
24. Peng DF, Razvi M, Chen H, Washington K, Roessner A, Schneider-Stock R, et al. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut. 2009; 58: 5-15. doi:10.1136/gut.2007.146290.
25. Kauer WK, Peters JH, DeMeester TR, Feussner H, Ireland AP, Stein HJ, et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery. 1997; 122: 874-81.
26. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005; 90: 139-46.
27. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002; 62:6823-6.
28. Pyo CW, Yang YL, Yoo NK, Choi SY. Reactive oxygen species activate HIV long terminal repeat via post-translational control of NF-kappaB. Biochemical and biophysical research communications. 2008; 376: 180-5. doi:10.1016/j.bbrc.2008.08.114.
29. Han YH, Park WH. Tiron, a ROS scavenger, protects human lung cancer Calu-6 cells against antimycin A-induced cell death. Oncol Rep. 2009; 21: 253-61.
30. Okamoto T, Sanda T, Asamitsu K. NF-kappa B signaling and carcinogenesis. Curr Pharm Des. 2007; 13: 447-62.
31. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest. 2001; 107: 7-11. doi:10.1172/JCI11830.
32. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 2000; 51: 511-23. doi:10.1146/annurev.med.51.1.511.
33. Wang F, Lv ZS, Fu YK. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Dis Esophagus. 2010; doi:10.1111/j.1442-2050.2010.01153.x.
34. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003; 124: 47-56. doi:10.1053/gast.2003.50008.
35. Aivaliotis IL, Pateras IS, Papaioannou M, Glytsou C, Kontzoglou K, Johnson EO, et al. How do cytokines trigger genomic instability? Journal of biomedicine & biotechnology. 2012; 2012: 536761. doi:10.1155/2012/536761.
36. Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett's carcinogenesis. Pathol Res Pract. 2012; 208: 269-80. doi:10.1016/j.prp.2012.03.007.
37. Kastelein F, Spaander MC, Steyerberg EW, Biermann K, ValkhoffVE, Kuipers EJ, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2013; 11: 382-8. doi:10.1016/j.cgh.2012.11.014.
38. Lada MJ, Nieman DR, Han M, Timratana P, Alsalahi O, Peyre CG, et al. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited. Surgery. 2013; 154: 856-66. doi:10.1016/j.surg.2013.07.020.
39. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology. 2010; 138: 2260-6. doi:10.1053/j.gastro.2010.02.045.
40. Goldman A, Condon A, Adler E, Minnella M, Bernstein C, Bernstein H, et al. Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells. Diseases of the esophagus: official journal of the International Society for Diseases of the Esophagus/ISDE. 2010; 23: 83-93. doi:10.1111/j.1442-2050.2009.00993.x.
41. Bozikas A, Marsman WA, Rosmolen WD, van Baal JW, Kulik W, ten Kate FJ, et al. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. Diseases of the esophagus :official journal of the International Society for Diseases of the Esophagus/ISDE. 2008; 21: 346-54. doi:10.1111/j.1442-2050.2007.00782.x.
42. Jurgens S, Meyer F, Spechler SJ, Souza R. The role of bile acids in the neoplastic progression of Barrett's esophagus - a short representative overview. Z Gastroenterol. 2012; 50: 1028-34. doi:10.1055/s-0032-1312922.
43. Cronin J, Williams L, McAdam E, Eltahir Z, Griffiths P, Baxter J, et al. The role of secondary bile acids in neoplastic development in the oesophagus. Biochemical Society transactions. 2010; 38: 337-42. doi:10.1042/BST0380337.
44. Zhang R, Yin X, Shi H, Wu J, Shakya P, Liu D, et al. Adiponectin Modulates DCA-Induced Inflammation via the ROS/NF-Kappa B Signaling Pathway in Esophageal Adenocarcinoma Cells. Dig Dis Sci. 2013; doi:10.1007/s10620-013-2877-5.
45. Barrett CW, Ning W, Chen X, Smith JJ, Washington MK, Hill KE, et al. Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res. 2013; 73: 1245-55. doi:10.1158/0008-5472.CAN-12-3150.
46. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998; 83: 2049-53.
47. Forman D. Re: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97: 1013-4.